Twenty four patients with pure motor neuropathy are reported.
led, in most patients, to an initial diagnosis of motor neuron disease. In some patients (nine of 24) , there was no appreciable muscle atrophy. Tendon reflexes were often absent or weak. The finding of persistent multifocal conduction block confined to motor nerve fibres raises questions about the nature and the importance of this syndrome. Segmental reduction of motor conduction velocity occurred at the site of the block, but significant slowing of motor nerve conduction was not found outside this site. The response to intravenous IVIg treatment seems to be correlated with the absence of amyotrophy. Patients with little or no amyotrophy had an initial and sustained response to IVIg, and did not develop amyotrophy during the follow up study. They could be considered to have a variant of chronic inflammatory demyelinating polyneuropathy. Patients with pronounced amyotrophy independent of the disease duration did not respond as well to IVIg treatment, suggesting the existence of a distinct entity. Among the patients treated about two thirds who had an initial good response to IVIg had high or significant antiganglioside GM1 (anti-GM1) antibody titres, but there was no correlation between the high titres before treatment and long lasting response to IVIg treatment.
(J Neurol Neurosurg Psychiatry 1995;59: [38] [39] [40] [41] [42] [43] [44] Keywords: motor neuropathy; conduction block; anti-GM1 antibodies; immunoglobulin treatment Since the description, by Lewis et al in 1982,' of a multifocal chronic sensory-motor peripheral neuropathy with persistent conduction blocks, pure multifocal motor neuropathy with persistent conduction blocks has been widely reported.2 2 The patients have multiple mononeuropathy with purely motor manifestations. There is asymmetric weakness with various degrees of amyotrophy, cramps, fasciculations, and preserved or abolished tendon reflexes. Most patients were initially diagnosed as having motor neuron disease. In some cases, the presence of a high serum anti-GM1 antibody titre5 10 13 19 and the response to immunosuppressive treatment2' 26 suggested an immunopathological mechanism. This was supported by the fact that anti-GM1 antibodies bind at the node of Ranvier,27 and that demyelination occurs at the site of the conduction block.28
Although some authors20' suggest that multifocal motor neuropathy may be a variant of a chronic inflammatory demyelinating polyneuropathy, many questions persist concerning the nature of the underlying process, the natural history, the homogeneity of the syndrome,'9 3"33 and its response to treatment.
We report here the clinical, electrophysiological, histological, and biological findings and response to treatment in 24 Needle EMG examination was performed in all patients. The incidence of spontaneous activity at rest (fibrillation potentials and positive sharp waves) was recorded. The size of motor unit potentials (MUPs) and the pattern of recruitment during maximal effort were also analysed.
Motor nerve conduction studies were performed with supramaximal percutaneous nerve stimulation, whereas compound muscle action potentials (CMAPs) were recorded with surface electrodes. For all patients, median, ulnar, and peroneal nerves were examined on both sides. The median nerve was stimulated at the wrist, elbow, axilla, and Erb's point. The ulnar nerve was stimulated at the wrist, below and above the elbow, on the axilla, and at Erb's point. At Erb's point, the nerve was stimulated with monopolar electrodes. We did not systematically search for conduction block in the radial nerve, as this was considered unreliable. The peroneal nerve was stimulated at the ankle, below and above the fibular head. For all nerve conduction studies skin temperature was maintained at 36°C. Distal latencies, conduction velocity, evoked motor response amplitudes (baseline to negative peak), and areas under the negative phase and its duration were measured. In upper limbs, the nerves were stimulated at five sites, corresponding to four segments. No segments exceeded 25 cm in length. Variation in the proximal/distal amplitude and area ratio and conduction velocity were measured for each segment. Latencies for F waves were measured after distal supramaximal stimulation (at least 16 stimuli) in the median, ulnar, and peroneal nerves.
Sensory nerve conduction and amplitude were measured in the median, ulnar, superficial peroneal, and sural nerves with surface recording and stimulating electrodes. The nerves were stimulated by orthodromic techniques in the upper limbs and antidromic techniques in the lower limbs. Amplitudes were measured peak to peak.
To determine if the reduction in amplitude was due to conduction block, or temporal dispersion, or both, we analysed the amplitude, area, and duration of the negative phase of the CMAP elicited from each site of stimulation. Between Erb's point and the axilla, a loss of 50% of the CMAP amplitude and area after proximal stimulation suggested a possible partial conduction block. More distally a loss of 30% was considered sufficient to confirm the block. The reduction of CMAP amplitude was considered to be due to temporal dispersion if the duration of the CMAP increased by more than 30% and the corresponding loss of area did not exceed 50%. The amplitude and area changes occurred abruptly over each nerve segment rather than as gradual losses along the length of the nerve.
HISTOLOGICAL EXAMINATIONS
Morphological examination of a sensory nerve (radial cutaneous), including teased fibre studies, was performed in 12 patients under local anaesthesia. The nerve specimens were fixed in 3-6% glutaraldehyde. The fragments were postfixed in osmium tetroxide. One nerve fragment was studied by teasing the endoneurial content. Another was embedded in epon and thionin stained 1 ju thick sections were examined.
BIOLOGICAL EXAMINATIONS
Serum enzymes and conventional biological variables were assayed. Protein immunoelectrophoresis was performed and CSF was examined. In all cases, the patients were sampled before immunosuppressive treatment. Anti-GM1 antibody titres were measured by enzyme linked immunosorbent assay (ELISA) according to two techniques previously described. '8 34 Table 1 summarises these and they have been evaluated previously. 35 The results of the assays were expressed differently. In technique A, serum was considered to contain anti-GM1 antibodies when, at a 1:20 dilution, the optical density (OD) was more than 2 SD above the mean obtained with 10 internal standards (ODX). The titre was defined as the reciprocal of the serum dilution required to obtain the ODX. Thus in technique A, a titre > 20 was considered to be significant (+ ) and a titre > 100 was considered to be high (+ +). In technique B, serum was considered to contain anti-GM1 antibodies when, at a 1:100 dilution, the optical density was three times the mean of the normal controls at the same dilution. As reported by Sadiq et al,'7 anti-GM1 antibodies were found in normal serum up to a 1:400 dilution. The titre was considered significant (+) when antibodies were detected at 1:800 dilution, and high (+ +) when detected at > 1:3200. In technique B, all positive cases were confirmed by immunodetection on thin layer chromatography as described by Mailly et al'6 with serum at a 1:100 dilution. When positivity was not confirmed by thin layer chromatography the sample was considered to be negative. Controls consisted of patients with chronic inflammatory demyelinating polyneuropathy and normal subjects of the same age groups. (SD 2-5) years in the non-atrophied group (P = 0 033). In the first group the onset of amyotrophy always appeared during the first year of evolution.
Fasciculations were seen in 17 of 24 patients, usually in the involved limb, whereas myokymia occurred in only two patients. The tendon reflexes were weak or abolished in the involved territories in 17 of 24 patients. They were brisk without Babinski's sign in only one patient, who spontaneously improved and whose deficit was localised in the right distal upper limb. ELECTROPHYSIOLOGICAL 
CHARACTERISTICS
In the upper limbs, conduction blocks were found at proximal sites between Erb's point and the axilla, at intermediate sites between axilla and elbow, and at distal sites below the elbow. In lower limbs, the conduction blocks were located only below or in the area of the fibular head on the peroneal nerve. Conduction blocks were always found in the upper limbs. In the lower limbs conduction blocks were only found in six patients. The location of conduction blocks was similar in both nerves and there were no predominant sites in the distribution of the conduction blocks. In all cases, the degree of the conduction block exceeded 50%, which excluded a reduction of the CMAP area due to an interphase cancellation.37 Motor nerve conduction velocities were usually normal outside the site of the blocked segments. Across the blocked segments, the motor conduction velocity was sometimes greatly reduced. In one patient, a pronounced slowing of proximal conduction without associated conduction block was initially found, but distal amplitude was very low. After IVIg treatment, an improvement in distal CMAP amplitude was found and a proximal conduction block could therefore be demonstrated. Motor distal latencies were slightly prolonged in most patients: for the median nerve, 19 of 24 patients had latencies of more than 3-6 (mean (SD) 4-2 (0 7)) ms; for the ulnar nerve, 15 of 24 patients had latencies of more than 3 (mean 3-5 (0 9)) ms; for the peroneal nerve, and 12 of 24 had latencies of more than 5 (mean (1 1)) ms.
Distal CMAPs were considerably reduced in some blocked nerves, although in other blocked nerves in the same patient they were normal. In most patients, the reduction in CMAP amplitude was correlated with the degree of muscle atrophy. Group 1 = patients with amyotrophy; group 2 = patients without amyotrophy; transient = transient response to IVIg lasting no longer than six months; sustained = response to IVIg lasting longer than six months; follow up study = follow-up study after six months (mean duration = three years).
the score of the functional activity scale. Two patients showed no response to IVIg, but one was recently stabilised by an immunosuppressive drug (azathioprine). Six patients had a very good initial and sustained response that started after the first infusion. Five of them who had no muscle atrophy, had a one to two point gain on the MRC scale and two points or more on the functional activity scale, which persisted after six months. They were essentially those with radial involvement. Some of them totally recovered their wrist extension. The last one, with muscle atrophy, had a two point gain on the functional activity scale. it was absent, even after five years of evolution. It was, therefore, possible to distinguish two groups of patients according to the presence or absence of muscle atrophy. The duration of the disease was significantly longer in the patients with atrophy, although the amyotrophy did not depend on the duration. The amyotrophy was always present during the first year of the disease. Cramps and fasciculations were present in most patients, mainly at the onset of the symptoms.
Motor involvement usually interfered with daily living, but in most cases, less than expected from the intensity of the motor deficit and wasting. Patients did not have the same pattern of evolution: most, after an initial worsening, were stable, and motor involvement did not show the progression usually found in motor neuron disease. A few patients progressively worsened. One patient improved spontaneously.
Conduction blocks were found constantly in the upper limbs in all patients. These were usually multifocal with no site predominance, although in three patients who presented with monomelic upper limb involvement, conduction blocks were located proximally. In some cases, conduction blocks occurred without corresponding clinical motor deficit in the nerve territory, although in most of the patients there was a good correlation between conduction block and motor deficit.
A segmental reduction of motor nerve conduction velocity was found at the sites of blocks, contrasting, in proximal blocks, with normal or slightly reduced distal velocities, except in one case. It is difficult, however, to interpret the importance of the conduction failure because the type and size of fibres in which conduction velocity was measured were not the same. Conduction velocities through, and distal to, the site of block cannot therefore be compared.
F waves were altered in most of the nerves with conduction blocks, as already reported.9 Abnormal F waves in the absence of conduction blocks suggest more proximal involvement. In these patients, spinal cervical stimulation is thought to be helpful,9 but not in the six patients in whom it was performed in our series. In patients with motor neuron disease, F waves are never altered to the same degree.'8 Altogether, alteration of F waves seemed to be a reliable electrophysiological variable in this type of neuropathy.
Multifocal motor neuropathies are therefore in almost all cases associated with conduction blocks and segmental reduction of conduction velocity. In some cases, slowing of segmental conduction may precede the detection of a conduction block, as in one of our cases. It is more than likely that patients with multifocal motor neuropathy with segmental conduction slowing can be grouped together with patients with persistent conduction block.
In some patients an intermediate late response was found, which was considered to be an axon reflex.39 This response is never found in motor neuron disease, but occurs occasionally in patients with multifocal motor neuropathy and persistent conduction block.2
In some patients, we found a slight alteration of the SNAPs in the nerves tested, with or without motor conduction block, despite normal clinical examination of the different sensory modalities.
Minor abnormalities on biopsy specimens of the superficial radial nerve showed that sensory fibres were not completely spared. But these abnormalities were not predictive for response to immunosuppressive treatment as was reported by Sahenk et al. 40 In a few cases, subclinical involvement of sensory nerves was detected by electrophysiological examination. The slight electrophysiological abnormalities of SNAPs and the moderate morphological modifications of the radial cutaneous nerve in some patients could indicate that there is a continuum between purely motor neuropathies with conduction block and the sensory-motor neuropathies with conduction block of the type reported by Lewis et al. ' Abnormal sensory potentials have also been described in motor neuron disease.4 ' 42 We found high titres of anti-GM1 antibodies in 42% of patients with technique A and 35% with technique B and in none of the control groups with CIDP or normal controls, confirming the specificity of high titres of anti-GM1 antibodies in this group.'443 When using technique A and technique B, respectively 29% and 48% of the patients examined had no significant or detectable titres of anti-GM1 antibodies. It is known, however, that other autoantibodies can be found in this pathology and these should be assayed. In a previous study, Ben Younes-Chennoufi et al'8 found IgM reactivity against other glycolipids. The patients without anti-GMI antibodies nevertheless had the typical clinical and electrophysiological features of multifocal motor neuropathy. Low concentrations of anti-GM1 antibodies, which are non-specific, can be encountered in other neurological diseases such as amyotrophic lateral sclerosis and stroke as well as in normal controls.'6-'9303444 Zielasek et al,35 who evaluated those techniques and others, only found discrepancies for negative or low titres. The fact that there are natural antibodies with low titres in normal controls, however, does not negate the effect of high titres in autoimmune diseases. 45 All but five patients were treated by IVIg. Most of them improved initially, although only one third seemed to show a lasting response. Only one patient with amyotrophy who had an initial good response to IVIg treatment had a sustained response. The absence of amyotrophy therefore seemed to predict a good and prolonged response to IVIg treatment. The patients without amyotrophy, in our experience, did not develop muscle wasting during follow up. This finding seems to justify the separation of patients into two groups.
Among the patients treated, about two thirds with an initial good response to IVIg, whatever the subsequent responses, had high or significant anti-GM1 antibody titres, but less than half of the patients had high titres. 
